Massachusetts 2023-2024 Regular Session

Massachusetts House Bill H945

Introduced

2/16/23

Refer

2/16/23

Refer

2/22/24

Caption

To ensure prescription drug cost transparency and affordability

Latest MA H945 Activity

View All Events: MA 2023-2024 Regular Session H945

Companion Bills

MA H1056

Similar To Establishing a commission to study maximum allowable costs lists

MA H4634

Replaced by Study Order

Previously Filed As

MA S875

To promote transparency in prescription drug prices

MA SB376

Prescription Drug Affordability Board; established, drug cost affordability review, report.

MA SB376

Prescription Drug Affordability Board; established, drug cost affordability review, report.

MA H1201

To promote transparency in prescription drug prices

MA HB570

Prescription Drug Affordability Board; established, drug cost affordability review, report.

MA SB274

Prescription Drug Affordability Board; established, drug cost affordability review, report.

MA HB1724

Prescription Drug Affordability Board; established, drug cost affordability review, report.

MA SB957

Prescription Drug Affordability Board and Fund; established, drug cost affordability review, etc.

MA HB1596

Prescription Drug Affordability Board and Fund; established, report, drug cost affordability review.

MA S749

Relative to pharmaceutical access, costs and transparency

Similar Bills

MA S2492

Relative to pharmaceutical access, costs and transparency

MA H4910

Similar Bills

MA S749

Relative to pharmaceutical access, costs and transparency

MA S732

Relative to promoting comprehensive transparency in the pharmaceutical industry

MA H1176

Relative to promoting comprehensive transparency in the pharmaceutical industry

MA H4891

Similar Bills

MA S2499

Relative to pharmaceutical access, costs and transparency

MA S2520

Relative to pharmaceutical access, costs and transparency